Markets:

Overview

News

Currencies

International

Treasuries

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

5.925 +0.025 (+0.42%)

Streaming Delayed Price Updated: 11:10 AM EST, Jan 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 Next >

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

November 18, 2024

From Silence Therapeutics plc

Via Business Wire

Analyst Scoreboard: 4 Ratings For Silence Therapeutics ↗

November 15, 2024

Via Benzinga

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

November 14, 2024

From Silence Therapeutics plc

Via Business Wire

Analyst Expectations For Silence Therapeutics's Future ↗

August 16, 2024

Via Benzinga

The Analyst Landscape: 6 Takes On Silence Therapeutics ↗

June 20, 2024

Via Benzinga

What 7 Analyst Ratings Have To Say About Silence Therapeutics ↗

May 17, 2024

Via Benzinga

Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock ↗

April 22, 2024

Via Benzinga

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

November 13, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

August 27, 2024

From Silence Therapeutics plc

Via Business Wire

SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024 ↗

August 15, 2024

Silence Therapeutics just reported results for the second quarter of 2024.

Via InvestorPlace

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 15, 2024

From Silence Therapeutics plc

Via Business Wire

What 4 Analyst Ratings Have To Say About Silence Therapeutics ↗

March 13, 2024

Via Benzinga

The 3 Best Gene Editing Stocks to Buy in August 2024 ↗

August 07, 2024

These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.

Via InvestorPlace

Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks ↗

July 25, 2024

It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it.

Via InvestorPlace

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

June 27, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

June 24, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

June 20, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

May 30, 2024

From Silence Therapeutics plc

Via Business Wire

SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024 ↗

May 16, 2024

Silence Therapeutics just reported results for the first quarter of 2024.

Via InvestorPlace

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

May 16, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

April 30, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

April 29, 2024

From Silence Therapeutics plc

Via Business Wire

3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 ↗

April 11, 2024

Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.

Via InvestorPlace

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

April 08, 2024

From Silence Therapeutics plc

Via Business Wire

7 Biotech Stocks Ready to Ride the Sector’s Resurgence ↗

March 18, 2024

With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.

Via InvestorPlace

These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results ↗

March 14, 2024

Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday.

Via Benzinga

What's Going On With Silence Therapeutics Stock Today? ↗

March 13, 2024

Silence Therapeutics reports narrower Q4 loss, data from zerlasiran study, and strengthened cash position. In March 2024, Mallinckrodt notified Silence that they will not pursue further development of...

Via Benzinga

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

March 13, 2024

From Silence Therapeutics plc

Via Business Wire

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

March 13, 2024

From Silence Therapeutics plc

Via Business Wire

Earnings Scheduled For March 13, 2024 ↗

March 13, 2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.